Simvastatin in Critically Ill Patients with Covid-19

Simvastatin, a widely available and inexpensive drug that is included on the WHO list of essential medicines, was shown to have a high probability (96%) of improving outcomes (a combination of survival and length of time patients need support in an intensive care unit) when started as a treatment for critically ill patients with COVID-19, and a 92% chance of improving survival at 3 months. This equates to one life saved for every 33 patients treated with simvastatin. 2,684 critically ill patients were included at 141 hospitals across 13 countries.

Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials

Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19. Through harmonising two clinical trials – REMAP-CAP and LOVIT-COVID – over 2,500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital. It was shown that high-dose vitamin C did not improve outcomes for patients. This is the largest trial examining high-dose vitamin C in COVID-19 and provides evidence that high-dose vitamin C is not beneficial and suggests a high probability that it may be harmful.

Completed your eCRF Data Collectors V1.3 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your Eligibility Assessors V2.1 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your Immune Modulation V1.0 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your Corticosteroid V5.1 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your Antiviral V2.3 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your SIV - protocol + general V3.3 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your eCRF Data Collectors V1.3 training?

Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org

Completed your Eligibility Assessors V2.1 training?

Fill in the form and send the confirmation email to ukremap-cap@icnarc.org

Completed your Macrolide V3.0 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your Immunoglobulin V2.1 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your Immune Modulation V1.0 training?

Fill in the form and send the confirmation email to ukremap-cap@icnarc.org

Completed your Corticosteroid V5.1 training?

Fill in the form and send the confirmation email to ukremap-cap@icnarc.org

Completed your Antibiotic V3.0 training?

Fill in the form and send the confirmation email to ukremap-cap@icnarc.org

Completed your Antiviral V2.3 training?

Fill in the form and send the confirmation email to ukremap-cap@icnarc.org

Completed your training?

Fill in the form and send the confirmation email to ukremap-cap@icnarc.org

Completed your SIV - protocol + general V3.2 training?
Fill in the form and send the confirmation email to
ukremap-cap@icnarc.org
Completed your training?

Fill in the form and send the confirmation email to ukremap-cap@icnarc.org